Evidence map›Paper›PMID 31161299›Full record

ReviewMolecular biotechnology2019

Stopping Untreatable Pathogen Infections Using Peptide Ligands to Sabotage Pathogenic Cell Surface Proteins.

Kevin Roe

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Kevin Roe, San Jose, USA. kevin.roe@att.net.
Viavi Solutions (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Specifically targeted peptide ligands can sabotage pathogenic cell surface proteins and stop increasingly untreatable pathogen infections. Different approaches might be used to sabotage pathogenic cell surface proteins to stop infections. A conjugation treatment uses carefully selected genetically modified plasmids prepared in advance to activate a secondary immune system response neutralizing pathogens with a new, much larger cascade of antibodies. Non-conjugation treatment introduces genetically modified cells into the center of localized pathogen infections to produce peptide ligands; and another non-conjugation treatment introduces only the peptide ligands into the center of localized pathogen infections to sabotage pathogenic cell surface proteins used to specifically infect mammalian cells. Extensive and meticulous plasmid transfer experiments by two separate groups firmly support the feasibility of extremely rapid and thorough plasmid transfer necessary for the conjugation treatment. A third independent group introduced genetically modified bacteria into mammals, including several human volunteers, with safe and effective experimental results, which also firmly supports the feasibility of the first non-conjugation treatment. These three approaches offer several profound advantages compared to treatments using new antibiotics.

Indexed as

AnimalsAnti-Bacterial AgentsBacteriaBacterial InfectionsBacterial ProteinsBiotechnologyDrug Delivery SystemsDrug Resistance, BacterialHumansLigandsMembrane ProteinsPeptidesAnti-Bacterial AgentsBacterial ProteinsLigandsMembrane ProteinsPeptidesAntibiotic resistanceAntibiotic-resistant bacteriaBiotechnologyImmune systemPathogen infections

Identifiers

PMID31161299
OpenAlexW2948551516

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.